Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Advanced Cancer
- Anal Carcinoma
- Anal Cancer
- Biliary Cancer
- Cholangiocarcinoma
- Bile Duct Cancer
- Neuroendocrine Tumor
- Carcinoid Tumor
- Endometrial Carcinoma
- Endometrial Cancer
- Cervical Carcinoma
- Cervical Cancer
- Vulvar Carcinoma
- Vulvar Cancer
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer (SCLC)
- Mesothelioma
- Thyroid Carcinoma
- Thyroid Cancer
- Salivary Gland Carcinoma
- Salivary Gland Cancer
- Salivary Cancer
- Parotid Gland Cancer
- Advanced Solid Tumors
- Colorectal Carcinoma
Interventions
- BIOLOGICAL: pembrolizumab
- BIOLOGICAL: pembrolizumab
Sponsor
Merck Sharp & Dohme LLC